13 Dec 2023

ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data

Investors | Therapeutics

04 Dec 2023

Shareholder update to review AVA6000 Phase 1a data

Investors | Therapeutics

15 Nov 2023

Affimer^® biotherapeutics: The next generation of cancer therapies

Blogs | Therapeutics

23 Oct 2023

Issue of Equity and Total Voting Rights

Investors

20 Oct 2023

International Conference on Molecular Targets and Cancer Therapeutics, overview

Blogs

18 Oct 2023

Block Listing Application to AIM

Investors

05 Oct 2023

Avacta to present promising new data from Affimer^® and pre|CISION^TM platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Investors | Therapeutics

29 Sep 2023

Director/PDMR Shareholdings

Investors

28 Sep 2023

Interim Results for the Period Ending 30 June 2023

Investors

20 Sep 2023

Issue of Equity and Total Voting Rights

Investors